Sort
8,912 grants matching “sars cov 2”
OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core
$448,283,318Stuart D Katz · New York University School Of Medicine · OT2 · FY2021 · HL
HVTN 405/HPTN 1901 Characterizing SARS-CoV-2-specific immunity in convalescent individuals
$393,953,893Lawrence Corey · Fred Hutchinson Cancer Research Center · UM1 · FY2020 · AI
National Biomedical Information Services
$358,847,685Michael Huerta · National Library Of Medicine · ZIH · FY2023 · LM
National Biomedical Information Services
$347,681,166Jerry Sheehan · National Library Of Medicine · ZIH · FY2022 · LM
National Biomedical Information Services
$332,242,445Patricia Brennan · National Library Of Medicine · ZIH · FY2021 · LM
CoVPN Vaccine Site Preparation
$169,587,659Myron S Cohen · Family Health International · UM1 · FY2020 · AI
OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core
$109,438,442Stuart D Katz · New York University School Of Medicine · OT2 · FY2024 · HL
Frederick National Laboratory for Cancer Research (FNLCR) Center for SARS-CoV-2 Serological Sciences
$85,668,587Ethan Dmitrovsky · Leidos Biomedical Research, Inc. · N01 · FY2021 · CA
Completion of ACTIV-2 Study
$82,531,927Angee Greer · Ppd Development Lp · N01 · FY2022 · AI
Antiviral Program for Pandemics (APP) & NCATS: Accelerating Antiviral Development
$77,500,000Matthew Hall · National Center For Advancing Translational Sciences · ZIA · FY2022 · TR
ACTIV-6
$77,049,200Daniel K Benjamin · Duke University · U24 · FY2021 · TR
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections
$76,222,582Judith S. Currier · University Of California Los Angeles · UM1 · FY2023 · AI
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/
$71,500,000Judith S. Currier · University Of California Los Angeles · UM1 · FY2022 · AI
Development of outpatient antiviral cocktails against SARS-CoV-2 and other potential pandemic RNA viruses.
$69,058,677Jeffrey S Glenn · Stanford University · U19 · FY2022 · AI
AI-driven Structure-enabled Antiviral Platform (ASAP)
$67,673,902John Damon Chodera · Sloan-Kettering Inst Can Research · U19 · FY2022 · AI
Center for Antiviral Medicines & Pandemic Preparedness (CAMPP)
$67,624,156Sumit K Chanda · Scripps Research Institute, The · U19 · FY2022 · AI
QCRG Pandemic Response Program
$67,452,049Nevan J Krogan · University Of California, San Francisco · U19 · FY2022 · AI
Midwest AViDD Center
$66,431,207Reuben S Harris · University Of Minnesota · U19 · FY2022 · AI
Metropolitan AntiViral Drug Accelerator
$65,141,731David S Perlin · Hackensack University Medical Center · U19 · FY2022 · AI
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
$61,429,109Lawrence Corey · Fred Hutchinson Cancer Research Center · UM1 · FY2021 · AI
OTA-21-015A Post-Acute Sequelae of SARS-CoV-2 Infection Initiative: NYU Langone Health Clinical Science Core, Data Resource Core, and PASC Biorepository Core
$59,963,139Stuart D Katz · New York University School Of Medicine · OT2 · FY2023 · HL
Integrated Research Facility at Fort Detrick
$58,051,257Connie Schmaljohn · National Institute Of Allergy And Infectious Diseases · ZIC · FY2024 · AI
Frederick National Laboratory for Cancer Research (FNLCR) Center for SARS-CoV-2 Serological Sciences
$57,909,079Ethan Dmitrovsky · Leidos Biomedical Research, Inc. · N01 · FY2022 · CA
UTMB-Novartis Alliance for Pandemic Preparedness
$56,163,625Vineet D Menachery · University Of Texas Med Br Galveston · U19 · FY2022 · AI
CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
$55,953,346Lawrence Corey · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI